Markets:

Overview

News

Currencies

International

Treasuries

ProQR Therapeutics N.V. - Ordinary Shares (NQ:PRQR)

1.555 +0.105 (+7.24%)

Streaming Delayed Price Updated: 11:12 AM EST, Feb 18, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about ProQR Therapeutics N.V. - Ordinary Shares

< Previous 1 2 3 4 5 Next >

48 Biggest Movers From Yesterday ↗

September 10, 2021

Gainers Rocket Lab USA, Inc. (NASDAQ: RKLB) jumped 37.3% to settle at $20.72. Rocket Lab reported 1H sales of $29.5 million and announced it has been awarded a contract to deploy...

Via Benzinga

Here's Why ProQR Stock Surged on Thursday ↗

September 09, 2021

A new collaboration deal with Eli Lilly could be worth up to $1.3 billion.

Via The Motley Fool

Why ProQR Therapeutics's Stock Is Trading Higher Today ↗

September 09, 2021

ProQR Therapeutics's (NASDAQ:PRQR) shares are trading higher after the company announced Axiomer RNA editing licensing and research collaboration with Lilly. ProQR...

Via Benzinga

35 Stocks Moving In Thursday's Mid-Day Session ↗

September 09, 2021

Gainers Gevo, Inc. (NASDAQ: GEVO) shares climbed 36.6% to $7.91. Chevron and Gevo announced intent to pursue sustainable aviation fuel investment. Offerpad Solutions Inc (NYSE:...

Via Benzinga

Eli Lilly Inks Another RNA Collab, This Time With ProQR ↗

September 09, 2021

Eli Lilly And Co (NYSE: LLY) is doubling down on RNA research as it pens another pact with a quiet RNA editing player focused on neuroscience, ProQR...

Via Benzinga

21 Stocks Moving in Thursday's Pre-Market Session ↗

September 09, 2021

Gainers Cardiff Oncology, Inc. (NASDAQ: CRDF) rose 17.3% to $8.27 in pre-market trading after the company announced new data from its Phase 1b/2 trial in KRAS-mutated metastatic...

Via Benzinga

The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi's Pemphigus Trial Disappointment, Humanigen's COVID-19 Drug Denied Emergency Use Authorization ↗

September 09, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 8) Abbott Laboratories (NYSE:...

Via Benzinga

ProQR Therapeutics Stock Is Trading Higher On Antisense Oligonucleotide Development Pact ↗

May 04, 2021

Yarrow Biotechnology Inc, a newly created company by RTW Investments LP, has in-licensed exclusive rights to ProQR Therapeutics N.V.'s (NASDAQ: ...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

May 04, 2021

Gainers BioLine Rx (NASDAQ:BLRX) shares moved upwards by 65.2% to $5.27 during Tuesday's pre-market session. The market value of their outstanding shares is at $226.7...

Via Benzinga

An End to This Rare Syndrome Could Be an Opportunity for Investors ↗

April 07, 2021

A rare genetic disease that causes combined blindness and deafness may have a novel treatment in line after positive phase 1/2 trial results last month.

Via The Motley Fool

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.